<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">bioLytical Laboratories Inc.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:40bfb2b5-e58e-4ec7-a9a5-9697d6684337;id=39917</id> <rights type="text">Copyright 2024, bioLytical Laboratories Inc.</rights> <updated>2024-11-04T17:00:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/tCkS7djb7F200TNBOmeElA==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/tCkS7djb7F200TNBOmeElA==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/11/04/2974309/21560/en/bioLytical-Laboratories-Inc-Announces-Health-Canada-Authorization-of-its-rapid-INSTI-HCV-Antibody-Test-for-Professional-Use-in-Canada.html</id> <title type="text">bioLytical Laboratories Inc. Announces Health Canada Authorization of its rapid INSTI® HCV Antibody Test for Professional Use in Canada</title> <published>2024-11-04T17:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/11/04/2974309/21560/en/bioLytical-Laboratories-Inc-Announces-Health-Canada-Authorization-of-its-rapid-INSTI-HCV-Antibody-Test-for-Professional-Use-in-Canada.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Canadian market]]></content> <dc:identifier>2974309</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 04 Nov 2024 17:00 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://ml.globenewswire.com/Resource/Download/87198011-5a80-4b38-9aaa-dbdce8c7e5fc"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2024/11/04/2974309/21560/en/bioLytical-Laboratories-Inc-Announces-Health-Canada-Authorization-of-its-rapid-INSTI-HCV-Antibody-Test-for-Professional-Use-in-Canada.html"> <img src="https://ml.globenewswire.com/Resource/Download/87198011-5a80-4b38-9aaa-dbdce8c7e5fc" width="600" align="left" border="0" alt="INSTI HCV Antibody Test Package" title="bioLytical Laboratories" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Health</dc:subject> <dc:keyword>HCV Antibody Test</dc:keyword> <dc:keyword>HCV Rapid test</dc:keyword> <dc:keyword>HCV</dc:keyword> <dc:keyword>HEALTH CANADA</dc:keyword> <dc:keyword>infectious disease</dc:keyword> <dc:keyword>HEALTH</dc:keyword> <dc:keyword>MEDICAL TECHNOLOGY</dc:keyword> <dc:keyword>point of care tests (POCT)</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/08/23/2935048/0/en/bioLytical-Announces-Final-Results-of-Substantial-Issuer-Bid.html</id> <title type="text">bioLytical Announces Final Results of Substantial Issuer Bid</title> <published>2024-08-23T18:56:41Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/23/2935048/0/en/bioLytical-Announces-Final-Results-of-Substantial-Issuer-Bid.html" /> <content type="html"><![CDATA[<p align="justify">VANCOUVER, British Columbia, Aug. 23, 2024 (GLOBE NEWSWIRE) -- bioLytical Laboratories Inc. (the “Company” or “bioLytical”) announces that it has taken up and paid for 18,234,667 common shares (the “Purchased Shares”) at a price of CAD$0.15 per share under bioLytical’s substantial issuer bid (the “Offer”) for a total cost of CAD$2,735,200.05. The Purchased Shares represent approximately 6.20% of the common shares outstanding immediately prior to the purchase. After giving effect to the purchase, bioLytical has 275,702,595 common shares issued and outstanding.<br></p>]]></content> <dc:identifier>2935048</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Fri, 23 Aug 2024 18:57 GMT</dc:modified> <dc:subject>Financing Agreements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/06/27/2905267/21560/en/bioLytical-Donates-1200-HIV-Testing-Kits-Across-the-United-States-to-Support-National-HIV-Testing-Day.html</id> <title type="text">bioLytical Donates 1200 HIV Testing Kits Across the United States to Support National HIV Testing Day</title> <published>2024-06-27T13:00:24Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/06/27/2905267/21560/en/bioLytical-Donates-1200-HIV-Testing-Kits-Across-the-United-States-to-Support-National-HIV-Testing-Day.html" /> <content type="html"><![CDATA[bioLytical helps boost testing with free HIV rapid test donations to KFF and the Greater Than HIV campaign to support national testing efforts]]></content> <dc:identifier>2905267</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Thu, 27 Jun 2024 13:01 GMT</dc:modified> <dc:subject>Philanthropy</dc:subject> <dc:keyword>National HIV Testing Day</dc:keyword> <dc:keyword>NHTD</dc:keyword> <dc:keyword>Rapid Testing</dc:keyword> <dc:keyword>HIV</dc:keyword> <dc:keyword>HIV POC</dc:keyword> <dc:keyword>HIV testing</dc:keyword> <dc:keyword>Testing</dc:keyword> <dc:keyword>HIV Awareness</dc:keyword> <dc:keyword>HIV Prevention</dc:keyword> <dc:keyword>HIV/AIDS</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/19/2884598/21560/en/bioLytical-Laboratories-Inc-Announces-Launch-of-its-INSTI-HCV-Antibody-Test-for-Professional-Use-in-Australia.html</id> <title type="text">bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia</title> <published>2024-05-19T22:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/19/2884598/21560/en/bioLytical-Laboratories-Inc-Announces-Launch-of-its-INSTI-HCV-Antibody-Test-for-Professional-Use-in-Australia.html" /> <content type="html"><![CDATA[bioLytical launches the INSTI® HCV Antibody Test in Australia with its inclusion on the Australian Register of Therapeutic Goods (ARTG number: 448926)]]></content> <dc:identifier>2884598</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Sun, 19 May 2024 22:00 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>rapid testing</dc:keyword> <dc:keyword>HCV</dc:keyword> <dc:keyword>hepatitis C</dc:keyword> <dc:keyword>HCV Antibody Test</dc:keyword> <dc:keyword>Hepatitis Test</dc:keyword> <dc:keyword>HCV Rapid test</dc:keyword> <dc:keyword>hepatitis</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/11/22/2785065/21560/fr/bioLytical-Laboratories-Inc-fait-des-dons-de-tests-de-d%C3%A9pistage-pour-aider-%C3%A0-accro%C3%AEtre-l-acc%C3%A8s-international-au-d%C3%A9pistage-en-pr%C3%A9vision-de-la-Semaine-internationale-du-d%C3%A9pistage.html</id> <title type="text">bioLytical Laboratories Inc. fait des dons de tests de dépistage pour aider à accroître l'accès international au dépistage en prévision de la Semaine internationale du dépistage</title> <published>2023-11-22T22:10:53Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/11/22/2785065/21560/fr/bioLytical-Laboratories-Inc-fait-des-dons-de-tests-de-d%C3%A9pistage-pour-aider-%C3%A0-accro%C3%AEtre-l-acc%C3%A8s-international-au-d%C3%A9pistage-en-pr%C3%A9vision-de-la-Semaine-internationale-du-d%C3%A9pistage.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc., en partenariat avec l'ONG Coalition Plus, dirige le projet visant à promouvoir l'importance du dépistage rapide pendant la Semaine internationale du dépistage avec le don de tests rapides de dépistage dans le monde entier <pre>bioLytical Laboratories Inc., en partenariat avec l'ONG Coalition Plus, dirige le projet visant à promouvoir l'importance du dépistage rapide pendant la Semaine internationale du dépistage avec le don de tests rapides de dépistage dans le monde entier</pre>]]></content> <dc:identifier>2785065</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Wed, 22 Nov 2023 22:11 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/11/22/2785000/21560/en/bioLytical-Laboratories-Inc-Donates-Tests-to-Help-Boost-International-Testing-Access-Ahead-of-International-Testing-Week.html</id> <title type="text">bioLytical Laboratories Inc. Donates Tests to Help Boost International Testing Access Ahead of International Testing Week</title> <published>2023-11-22T18:30:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/11/22/2785000/21560/en/bioLytical-Laboratories-Inc-Donates-Tests-to-Help-Boost-International-Testing-Access-Ahead-of-International-Testing-Week.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. and NGO Coalition Plus Lead the Charge to Promote the Importance of Rapid Testing during International Testing Week]]></content> <dc:identifier>2785000</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Wed, 22 Nov 2023 18:30 GMT</dc:modified> <dc:subject>Calendar of Events</dc:subject> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>HIV</dc:keyword> <dc:keyword>testing</dc:keyword> <dc:keyword>international testing day</dc:keyword> <dc:keyword>HIV/AIDS</dc:keyword> <dc:keyword>INSTI</dc:keyword> <dc:keyword>biolytical</dc:keyword> <dc:keyword>Coalition PLUS</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/03/27/2634831/21560/zh-hans/bioLytical-Laboratories-Inc-%E7%9A%84INSTI-%E5%A4%9A%E9%87%8DHIV-1-2%E6%A2%85%E6%AF%92%E6%8A%97%E4%BD%93%E6%A3%80%E6%B5%8B%E8%AF%95%E5%89%82%E7%9B%92%E8%8E%B7%E5%BE%97%E5%8A%A0%E6%8B%BF%E5%A4%A7%E5%8D%AB%E7%94%9F%E9%83%A8%E6%8E%88%E6%9D%83.html</id> <title type="text">bioLytical Laboratories Inc.的INSTI®多重HIV-1/2梅毒抗体检测试剂盒获得加拿大卫生部授权</title> <published>2023-03-27T13:07:34Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/03/27/2634831/21560/zh-hans/bioLytical-Laboratories-Inc-%E7%9A%84INSTI-%E5%A4%9A%E9%87%8DHIV-1-2%E6%A2%85%E6%AF%92%E6%8A%97%E4%BD%93%E6%A3%80%E6%B5%8B%E8%AF%95%E5%89%82%E7%9B%92%E8%8E%B7%E5%BE%97%E5%8A%A0%E6%8B%BF%E5%A4%A7%E5%8D%AB%E7%94%9F%E9%83%A8%E6%8E%88%E6%9D%83.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc.今天宣布已在加拿大启动其面向专业使用的INSTI®多重HIV-1/2梅毒抗体检测试剂盒 <pre>bioLytical Laboratories Inc.今天宣布已在加拿大启动其面向专业使用的INSTI®多重HIV-1/2梅毒抗体检测试剂盒</pre>]]></content> <dc:identifier>2634831</dc:identifier> <dc:language>zh-hans</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 27 Mar 2023 13:08 GMT</dc:modified> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/03/27/2634831/21560/es/bioLytical-Laboratories-Inc-obtiene-autorizaci%C3%B3n-de-Health-Canada-para-su-prueba-de-anticuerpos-INSTI-Multiplex-VIH-1-2-y-S%C3%ADfilis.html</id> <title type="text">bioLytical Laboratories Inc. obtiene autorización de Health Canada para su prueba de anticuerpos INSTI® Multiplex VIH-1/2 y Sífilis</title> <published>2023-03-27T13:07:34Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/03/27/2634831/21560/es/bioLytical-Laboratories-Inc-obtiene-autorizaci%C3%B3n-de-Health-Canada-para-su-prueba-de-anticuerpos-INSTI-Multiplex-VIH-1-2-y-S%C3%ADfilis.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. anunció hoy que lanzó su prueba de anticuerpos INSTI® Multiplex VIH-1/2 y Sífilis para uso profesional en Canadá. <pre>bioLytical Laboratories Inc. anunció hoy que lanzó su prueba de anticuerpos INSTI® Multiplex VIH-1/2 y Sífilis para uso profesional en Canadá.</pre>]]></content> <dc:identifier>2634831</dc:identifier> <dc:language>es</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 27 Mar 2023 13:08 GMT</dc:modified> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/03/27/2634692/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-its-INSTI-Multiplex-HIV-1-2-Syphilis-Antibody-Test.html</id> <title type="text">bioLytical Laboratories Inc. Receives Health Canada Authorization for its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test</title> <published>2023-03-27T12:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/03/27/2634692/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-its-INSTI-Multiplex-HIV-1-2-Syphilis-Antibody-Test.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. announced today that it has launched its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test for professional use in Canada <pre>bioLytical Laboratories Inc. announced today that it has launched its INSTI® Multiplex HIV-1/2 Syphilis Antibody Test for professional use in Canada</pre>]]></content> <dc:identifier>2634692</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 27 Mar 2023 12:01 GMT</dc:modified> <media:content medium="image" type="image/png" width="600" url="https://ml.globenewswire.com/Resource/Download/4adaf035-89ca-428d-a01d-9bf5c3f05e4b"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2023/03/27/2634692/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-its-INSTI-Multiplex-HIV-1-2-Syphilis-Antibody-Test.html"> <img src="https://ml.globenewswire.com/Resource/Download/4adaf035-89ca-428d-a01d-9bf5c3f05e4b" width="600" align="left" border="0" alt="Multiplex Package - Canada" title="INSTI® Multiplex HIV-1/2 Syphilis Antibody Test Package" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Health</dc:subject> <dc:keyword>syphilis</dc:keyword> <dc:keyword>hiv</dc:keyword> <dc:keyword>point of care tests (POCT)</dc:keyword> <dc:keyword>rapid</dc:keyword> <dc:keyword>rapid testing</dc:keyword> <dc:keyword>multiplex</dc:keyword> <dc:keyword>infectious disease</dc:keyword> <dc:keyword>accessible testing</dc:keyword> <dc:keyword>Antibody tesitng</dc:keyword> <dc:keyword>test</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/10/18/2536869/21560/es/bioLytical-Laboratories-Inc-obtiene-PQ-de-la-OMS-para-su-prueba-casera-de-ant%C3%ADgeno-iStatis-COVID-19.html</id> <title type="text">bioLytical Laboratories Inc. obtiene PQ de la OMS para su prueba casera de antígeno iStatis COVID-19</title> <published>2022-10-18T19:02:29Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/10/18/2536869/21560/es/bioLytical-Laboratories-Inc-obtiene-PQ-de-la-OMS-para-su-prueba-casera-de-ant%C3%ADgeno-iStatis-COVID-19.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. anunció su entrada inmediata a los mercados de África, Asia, Oriente Medio y América del Sur con su prueba de autodiagnóstico de antígeno COVID-19 en su nueva plataforma de flujo lateral, iStatis <pre>bioLytical Laboratories Inc. anunció su entrada inmediata a los mercados de África, Asia, Oriente Medio y América del Sur con su prueba de autodiagnóstico de antígeno COVID-19 en su nueva plataforma de flujo lateral, iStatis</pre>]]></content> <dc:identifier>2536869</dc:identifier> <dc:language>es</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Tue, 18 Oct 2022 19:02 GMT</dc:modified> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/10/18/2536045/21560/en/bioLytical-Laboratories-Inc-receives-WHO-PQ-for-its-iStatis-COVID-19-Antigen-Home-Test.html</id> <title type="text">bioLytical Laboratories Inc. receives WHO PQ for its iStatis COVID-19 Antigen Home Test</title> <published>2022-10-18T08:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/10/18/2536045/21560/en/bioLytical-Laboratories-Inc-receives-WHO-PQ-for-its-iStatis-COVID-19-Antigen-Home-Test.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. announced its immediate entry into the African, Asian, Middle Eastern, and South American markets with its COVID-19 antigen self-test on its new lateral flow platform, iStatis <pre>bioLytical Laboratories Inc. announced its immediate entry into the African, Asian, Middle Eastern, and South American markets with its COVID-19 antigen self-test on its new lateral flow platform, iStatis</pre>]]></content> <dc:identifier>2536045</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Tue, 18 Oct 2022 08:00 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://ml.globenewswire.com/Resource/Download/1f99cf04-8303-4204-8a66-fe352eb5f47e"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2022/10/18/2536045/21560/en/bioLytical-Laboratories-Inc-receives-WHO-PQ-for-its-iStatis-COVID-19-Antigen-Home-Test.html"> <img src="https://ml.globenewswire.com/Resource/Download/1f99cf04-8303-4204-8a66-fe352eb5f47e" width="600" align="left" border="0" alt="iStatis COVID-19 Antigen Home Test" title="iStatis COVID-19 Antigen Home Test Components" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Health</dc:subject> <dc:keyword>COVID-19</dc:keyword> <dc:keyword>covid-19 antigen home test</dc:keyword> <dc:keyword>covid-19 test</dc:keyword> <dc:keyword>covid-19 testing</dc:keyword> <dc:keyword>COVID-19 WHO</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/04/04/2415954/21560/fr/bioLytical-Laboratories-Inc-re%C3%A7oit-l-autorisation-de-Sant%C3%A9-Canada-pour-le-test-%C3%A0-domicile-de-d%C3%A9pistage-antig%C3%A9nique-de-la-COVID-19-iStatis.html</id> <title type="text">bioLytical Laboratories Inc. reçoit l'autorisation de Santé Canada pour le test à domicile de dépistage antigénique de la COVID-19 iStatis</title> <published>2022-04-04T15:21:14Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/04/04/2415954/21560/fr/bioLytical-Laboratories-Inc-re%C3%A7oit-l-autorisation-de-Sant%C3%A9-Canada-pour-le-test-%C3%A0-domicile-de-d%C3%A9pistage-antig%C3%A9nique-de-la-COVID-19-iStatis.html" /> <content type="html"><![CDATA[<p align="left"><em>bioLytical Laboratories Inc. a annoncé aujourd'hui le lancement d'un deuxième test sur sa nouvelle plateforme iStatis, après avoir reçu l'autorisation de Santé Canada pour l'entrée immédiate sur le marché canadien de son test à domicile de dépistage antigénique de la COVID-19 iStatis</em><br></p>]]></content> <dc:identifier>2415954</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 04 Apr 2022 15:21 GMT</dc:modified> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/04/02/2415135/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-the-iStatis-COVID-19-Antigen-Home-Test.html</id> <title type="text">bioLytical Laboratories Inc. Receives Health Canada Authorization for the iStatis COVID-19 Antigen Home Test</title> <published>2022-04-02T00:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/04/02/2415135/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-the-iStatis-COVID-19-Antigen-Home-Test.html" /> <content type="html"><![CDATA[<p align="left"><em>bioLytical Laboratories Inc. announced today that it is launching a second test on its new platform, iStatis, after receiving Health Canada authorization for the iStatis COVID-19 Antigen Home Test for its immediate market entry into Canada</em><br></p>]]></content> <dc:identifier>2415135</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Sat, 02 Apr 2022 00:00 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://ml.globenewswire.com/Resource/Download/ab1ff29b-b95a-4eb2-b640-2c03ab35d28a"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2022/04/02/2415135/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-the-iStatis-COVID-19-Antigen-Home-Test.html"> <img src="https://ml.globenewswire.com/Resource/Download/ab1ff29b-b95a-4eb2-b640-2c03ab35d28a" width="600" align="left" border="0" alt="iStatis COVID-19 Antigen Test Pouch" title="the iStatis COVID-19 Antigen Home Test is Here! " /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>COVID-19</dc:keyword> <dc:keyword>covid-19 testing</dc:keyword> <dc:keyword>covid-19 antigen home test</dc:keyword> <dc:keyword>antigen testing</dc:keyword> <dc:keyword>Rapid Testing</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/03/21/2406710/21560/fr/bioLytical-Laboratories-Inc-re%C3%A7oit-son-marquage-CE-pour-le-test-antig%C3%A9nique-%C3%A0-domicile-de-la-COVID-19-iStatis.html</id> <title type="text">bioLytical Laboratories Inc. reçoit son marquage CE pour le test antigénique à domicile de la COVID-19 iStatis</title> <published>2022-03-21T12:31:22Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/03/21/2406710/21560/fr/bioLytical-Laboratories-Inc-re%C3%A7oit-son-marquage-CE-pour-le-test-antig%C3%A9nique-%C3%A0-domicile-de-la-COVID-19-iStatis.html" /> <content type="html"><![CDATA[<p><em>bioLytical Laboratories Inc. a annoncé aujourd'hui le lancement d'une nouvelle plateforme, iStatis, et a reçu son marquage CE pour l'entrée immédiate sur le marché européen de son test antigénique à domicile de la COVID-19 iStatis</em><br></p>]]></content> <dc:identifier>2406710</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 21 Mar 2022 12:32 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>Antigen test</dc:keyword> <dc:keyword>COVID-19</dc:keyword> <dc:keyword>covid-19 antigen home test</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/03/21/2406710/21560/de/bioLytical-Laboratories-Inc-erh%C3%A4lt-CE-Kennzeichnung-f%C3%BCr-iStatis-COVID-19-Antigentest-f%C3%BCr-den-Heimgebrauch.html</id> <title type="text">bioLytical Laboratories Inc. erhält CE-Kennzeichnung für iStatis COVID-19-Antigentest für den Heimgebrauch</title> <published>2022-03-21T12:31:22Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/03/21/2406710/21560/de/bioLytical-Laboratories-Inc-erh%C3%A4lt-CE-Kennzeichnung-f%C3%BCr-iStatis-COVID-19-Antigentest-f%C3%BCr-den-Heimgebrauch.html" /> <content type="html"><![CDATA[<p><em>bioLytical Laboratories Inc. hat heute bekanntgegeben, dass das Unternehmen eine neue Plattform, iStatis, auf den Markt bringt, und hat die CE-Kennzeichnung für den sofortigen Markteintritt in Europa für seinen iStatis COVID-19-Antigentest für den Heimgebrauch erhalten</em></p>]]></content> <dc:identifier>2406710</dc:identifier> <dc:language>de</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 21 Mar 2022 12:32 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>Antigen test</dc:keyword> <dc:keyword>COVID-19</dc:keyword> <dc:keyword>covid-19 antigen home test</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/03/21/2406425/21560/en/bioLytical-Laboratories-Inc-Receives-its-CE-Mark-for-the-iStatis-COVID-19-Antigen-Home-Test.html</id> <title type="text">bioLytical Laboratories Inc. Receives its CE Mark for the iStatis COVID-19 Antigen Home Test</title> <published>2022-03-21T09:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/03/21/2406425/21560/en/bioLytical-Laboratories-Inc-Receives-its-CE-Mark-for-the-iStatis-COVID-19-Antigen-Home-Test.html" /> <content type="html"><![CDATA[<p align="left"><em>bioLytical Laboratories Inc. announced today that it is launching a new platform, iStatis, and has received its CE Mark for immediate market entry into Europe for its iStatis COVID-19 Antigen Home Test</em><br></p>]]></content> <dc:identifier>2406425</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 21 Mar 2022 09:00 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://ml.globenewswire.com/Resource/Download/1f4f21c7-51bc-481a-9b13-d4c00f6c2697"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2022/03/21/2406425/21560/en/bioLytical-Laboratories-Inc-Receives-its-CE-Mark-for-the-iStatis-COVID-19-Antigen-Home-Test.html"> <img src="https://ml.globenewswire.com/Resource/Download/1f4f21c7-51bc-481a-9b13-d4c00f6c2697" width="600" align="left" border="0" alt="HT components together-Long Swab_CE" title="The iStatis COVID-19 Antigen Home Test Kit Components" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>Antigen test</dc:keyword> <dc:keyword>COVID-19</dc:keyword> <dc:keyword>covid-19 antigen home test</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/03/07/2398064/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-its-iStatis-COVID-19-Antigen-Test.html</id> <title type="text">bioLytical Laboratories Inc. Receives Health Canada Authorization for its iStatis COVID-19 Antigen Test</title> <published>2022-03-07T14:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/03/07/2398064/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-its-iStatis-COVID-19-Antigen-Test.html" /> <content type="html"><![CDATA[bioLytical Laboratories Inc. announced today that it is launching a new platform, iStatis, and has received Health Canada authorization for immediate market entry into Canada for its first product, the iStatis COVID-19 Antigen Test <pre>bioLytical Laboratories Inc. announced today that it is launching a new platform, iStatis, and has received Health Canada authorization for immediate market entry into Canada for its first product, the iStatis COVID-19 Antigen Test</pre>]]></content> <dc:identifier>2398064</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Mon, 07 Mar 2022 14:01 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://ml.globenewswire.com/Resource/Download/d449568c-b104-4fd8-8eb7-e5ea5893d807"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2022/03/07/2398064/21560/en/bioLytical-Laboratories-Inc-Receives-Health-Canada-Authorization-for-its-iStatis-COVID-19-Antigen-Test.html"> <img src="https://ml.globenewswire.com/Resource/Download/d449568c-b104-4fd8-8eb7-e5ea5893d807" width="600" align="left" border="0" alt="POC components together-Short Swab" title="iStatis COVID-19 Antigen Test for Professional Use" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>COVID-19</dc:keyword> <dc:keyword>covid-19 test</dc:keyword> <dc:keyword>Rapid Testing</dc:keyword> <dc:keyword>biotech</dc:keyword> <dc:keyword>HEALTH CANADA</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/11/03/2119127/21560/en/Health-Canada-Approves-Canada-s-First-HIV-Self-Test.html</id> <title type="text">Health Canada Approves Canada’s First HIV Self Test</title> <published>2020-11-03T11:00:00Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/11/03/2119127/21560/en/Health-Canada-Approves-Canada-s-First-HIV-Self-Test.html" /> <content type="html"><![CDATA[Made-In-Canada INSTI® HIV Self Test Provides Results in 1 Minute and is More Than 99% Accurate <pre>Made-In-Canada INSTI® HIV Self Test Provides Results in 1 Minute and is More Than 99% Accurate</pre>]]></content> <dc:identifier>2119127</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Tue, 03 Nov 2020 11:00 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:keyword>biotech</dc:keyword> <dc:keyword>HIV Self Test</dc:keyword> <dc:keyword>HIV Testing</dc:keyword> <dc:keyword>HIV</dc:keyword> <dc:keyword>HIV/AIDS</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/10/16/2109925/21560/fr/bioLytical-Laboratories-annonce-le-lancement-d-INSTI-un-test-de-d%C3%A9pistage-des-anticorps-%C3%A0-la-COVID-19-avec-des-r%C3%A9sultats-disponibles-en-une-minute.html</id> <title type="text">bioLytical Laboratories annonce le lancement d'INSTI®, un test de dépistage des anticorps à la COVID-19 avec des résultats disponibles en une minute</title> <published>2020-10-16T14:52:59Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/10/16/2109925/21560/fr/bioLytical-Laboratories-annonce-le-lancement-d-INSTI-un-test-de-d%C3%A9pistage-des-anticorps-%C3%A0-la-COVID-19-avec-des-r%C3%A9sultats-disponibles-en-une-minute.html" /> <content type="html"><![CDATA[<p align="left">VANCOUVER, Colombie-Britannique, 16 oct. 2020 (GLOBE NEWSWIRE) -- bioLytical Laboratories a annoncé aujourd'hui la sortie en Europe d'un nouveau test de détection des anticorps contre la COVID-19 dont les résultats sont disponibles en une minute, suite à la réception de l'homologation CE, confirmant que le produit répond aux normes de sécurité européennes.</p>]]></content> <dc:identifier>2109925</dc:identifier> <dc:language>fr</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Fri, 16 Oct 2020 14:53 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2020/10/16/2109925/21560/de/bioLytical-Laboratories-k%C3%BCndigt-Markteinf%C3%BChrung-von-1-min%C3%BCtigem-INSTI-COVID-19-Antik%C3%B6rpertest-an.html</id> <title type="text">bioLytical Laboratories kündigt Markteinführung von 1-minütigem INSTI®-COVID-19-Antikörpertest an</title> <published>2020-10-16T14:52:59Z</published> <updated>2024-11-16T03:23:23Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2020/10/16/2109925/21560/de/bioLytical-Laboratories-k%C3%BCndigt-Markteinf%C3%BChrung-von-1-min%C3%BCtigem-INSTI-COVID-19-Antik%C3%B6rpertest-an.html" /> <content type="html"><![CDATA[<p>VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- bioLytical Laboratories hat heute die Markteinführung eines neuen 1-minütigen COVID-19-Antikörpertests in Europa bekanntgegeben. Zuvor hat es für sein Produkt die CE-Kennzeichnung erhalten, die belegt, dass der Test die europäischen Sicherheitsstandards erfüllt.</p>]]></content> <dc:identifier>2109925</dc:identifier> <dc:language>de</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>bioLytical Laboratories Inc.</dc:contributor> <dc:modified>Fri, 16 Oct 2020 14:53 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> </feed>